Allogene Therapeutics (ALLO) Total Current Liabilities (2018 - 2026)

Allogene Therapeutics has reported Total Current Liabilities for 9 years, with the latest figure at $28.3 million in Q1 2026.

• Quarterly Total Current Liabilities fell 5.64% year-over-year to $28.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.3 million (down 5.64% YoY) and the FY2025 annual result came in at $32.5 million, down 8.47% from the prior year.
• Total Current Liabilities fell to $28.3 million in Q1 2026 per ALLO's latest filing, from $32.5 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $59.4 million in Q1 2023 and troughed at $28.3 million in Q1 2026.
• A 5-year average of $38.9 million and a median of $36.6 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities surged 62.21% in 2023, then slumped 47.99% in 2024.
• Over 5 years, Total Current Liabilities stood at $53.7 million in 2022, then sank by 30.99% to $37.1 million in 2023, then decreased by 4.2% to $35.5 million in 2024, then declined by 8.47% to $32.5 million in 2025, then fell by 12.87% to $28.3 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $28.3 million, $32.5 million, and $31.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.